MedMira Inc. (TSXV:MIR)

Market Cap	45.61M -18.8%
Revenue (ttm)	370.57K +45.7%
Net Income	-2.99M
EPS	-0.00
Shares Out	701.73M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,830
Open	0.0650
Previous Close	0.0650
Day's Range	0.0650 - 0.0650
52-Week Range	0.0500 - 0.1050
Beta	0.80
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 27, 2026

About MedMira

MedMira Inc., a biotechnology company, researches, develops, manufactures, and sells rapid diagnostics and technology platforms in North America, Europe, and internationally. The company offers Reveal HIV, a test that detects antibodies to HIV-1 and HIV-2 in whole blood, serum, or plasma; Reveal TP, a rapid syphilis antibody test that detects treponema pallidum antibodies in serum, plasma, or whole blood; Multiplo, a line of multiplex tests for HIV-1/2, Hepatitis B and C, and syphilis; and Miriad triple product for preliminary screening of HIV ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 52
• Stock Exchange: TSX Venture Exchange
• Ticker Symbol: MIR

Financial Performance

In fiscal year 2025, MedMira's revenue was 240,509, a decrease of -41.70% compared to the previous year's 412,568. Losses were -4.52 million, 36.0% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 18, 2026

Data Sources Report a data error